<DOC>
	<DOC>NCT00439647</DOC>
	<brief_summary>This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.</brief_summary>
	<brief_title>Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>â€¢ Osteoporosis as defined by very low bone mineral density in the hip and spine or low bone mineral density in the hip combined with presence of 13 mild or moderate fractures of the vertebrae Low Vitamin D Renal insufficiency Previous treatment with certain antiosteoporotic therapies (except after certain washout periods): calcitonin, bisphosphonates, parathyroid hormone (PTH), sodium fluoride, strontium ranelate, Previous treatment with testosterone, anabolic steroids or growth hormone Chronic use of systemic corticosteroids (oral or i.v.) within the last year History of any cancer or metastases within the last 5 years History of brittle bone disease, multiple myeloma, or Paget's disease, or any other metabolic bone disease, except osteoporosis Bilateral hip replacements Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>males</keyword>
	<keyword>vertebral fractures</keyword>
	<keyword>clinical fractures</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>bone biomarkers</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>